ProQR Therapeutics reported a net loss of 13 million euros, or 0.33 euros per diluted share, in the fourth quarter of 2018 compared with a net loss of 11.3 million euros, or 0.39 euros per diluted share, in 2017’s final quarter, according to a press release.
For the full year, net loss totaled 37.1 million euros, or 1.09 euros per diluted share, compared with a net loss of 43.7 million euros, or 1.72 euros per diluted share, for 2017.
Research and development costs increased from 8.3 million euros to 9.5 million euros for the quarter and decreased from 31.1 million euros to 29.5 million
Uncategorized